v3.21.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash Flows From Operating Activities    
Net loss $ (26,451) $ (26,740)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 5,501 4,524
Interest accretion 549 440
Bad debt expense 585 499
Reversal of 2019 bonus accrual (1,156)
Mark to market on warrants (61) (279)
ESPP expense 55
Deferred income taxes 37 18
Change in estimate on collectability of accounts receivable 3,479
Change in fair value of contingent consideration (489) (44)
Asset impairment 37
Other gains and expenses, net 18
Other changes in operating assets and liabilities:    
Decrease (increase) in accounts receivable 1,725 (1,102)
Decrease in other current assets 241 129
Increase in other long-term assets (11)
Decrease in accounts payable (198) (938)
Increase in accrued salaries and bonus 1,976 362
Increase (decrease) in accrued liabilities 1,395 (1,301)
Increase in long-term liabilities 88 454
Net cash used in operating activities (13,979) (18,957)
Cash Flows From Investing Activity    
Acquisition of Biopharma, net of cash acquired (13,829)
Purchase of property and equipment (1,575) (131)
Sale of property and equipment 13
Net cash used in investing activities (1,575) (13,947)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 434 6,478
Issuance of preferred stock, net of expenses 25,744
Issuance of Series B preferred stock, net of expenses 19,223
Payment of CGIX note and related interest (6,024)
(Payments) borrowings on Line of Credit (3,000) 3,000
Cash paid for repurchase of restricted shares (52) (41)
Net cash provided by financing activities 16,605 29,157
Net increase (decrease) in cash, cash equivalents and restricted cash 1,051 (3,747)
Cash, cash equivalents and restricted cash - beginning 2,321 6,068
Cash, cash equivalents and restricted cash - ending $ 3,372 $ 2,321

Source